Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rania El-Lababidi

Showing results (11-20 of 24) with videos related to

Pageof 3
Sort By:
Frontiers in Pharmacology|March 7, 2022
Tocilizumab and COVID-19: Timing of Administration and EfficacyEmna Abidi, Wasim S El Nekidy, Eman Alefishat, et al.
Idcases|June 1, 2022
Outcomes of caspofungin use in the treatment of <i>Candida</i>-related urinary tract infections, a case seriesLaila Rkieh, Wasim S El Nekidy, Leen Oyoun Alsoud, et al.
Clinical Nephrology|July 13, 2023
Clinical outcomes of ceftolozane-tazobactam dosing in patients with sepsis undergoing renal replacement therapiesWasim S El Nekidy, Mooza Al Ali, Emna Abidi, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|June 15, 2017
Comparison of antimicrobial activity between ceftolozane-tazobactam and ceftazidime-avibactam against multidrug-resistant isolates of Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosaAdnan Alatoom, Hashim Elsayed, Karen Lawlor, et al.
Hemodialysis International. International Symposium on Home Hemodialysis|May 5, 2023
Microbiologic outcomes of ceftazidime-avibactam dosing in patients with sepsis utilizing renal replacement therapiesWasim S El Nekidy, Mooza Al Ali, Emna Abidi, et al.
The International Journal of Artificial Organs|July 30, 2024
Efficacy and safety of ertapenem dosing in patients with ESBL producing <i>Enterobacterales</i> infections utilizing renal replacement therapiesWasim S El Nekidy, Iyad Ghazal, Emna Abidi, et al.
Hospital Pharmacy|July 28, 2022
Is Cefoxitin a Carbapenem Sparing Agent in the Management of Urinary Tract Infections Caused by ESBL Producing <i>Enterobacterales</i>?Wasim S El Nekidy, Manal M Abdelsalam, Ahmad R Nusair, et al.
Antibiotics (Basel, Switzerland)|August 29, 2024
Clinical Outcomes of Ceftazidime-Avibactam versus Ceftolozane-Tazobactam in Managing Pseudomonal Infections in Patients Undergoing Renal Replacement TherapyWasim S El Nekidy, Mooza Al Ali, Emna Abidi, et al.
Antibiotics (Basel, Switzerland)|October 25, 2024
The Impact of Clinical Pharmacist-Driven Weekend Antimicrobial Stewardship Coverage at a Quaternary HospitalHazem Elrefaei, Wasim S El Nekidy, Rama Nasef, et al.
Pharmacotherapy|February 6, 2016
Therapeutic Advances in HCV Genotype 1 Infection: Insights from the Society of Infectious Diseases PharmacistsPaulina Deming, Michelle T Martin, Juliana Chan, et al.
Pageof 3

Showing results (11-20 of 24) with videos related to

Sort By:
Pageof 3
Frontiers in Pharmacology|March 7, 2022
Tocilizumab and COVID-19: Timing of Administration and EfficacyEmna Abidi, Wasim S El Nekidy, Eman Alefishat, et al.
Idcases|June 1, 2022
Outcomes of caspofungin use in the treatment of <i>Candida</i>-related urinary tract infections, a case seriesLaila Rkieh, Wasim S El Nekidy, Leen Oyoun Alsoud, et al.
Clinical Nephrology|July 13, 2023
Clinical outcomes of ceftolozane-tazobactam dosing in patients with sepsis undergoing renal replacement therapiesWasim S El Nekidy, Mooza Al Ali, Emna Abidi, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|June 15, 2017
Comparison of antimicrobial activity between ceftolozane-tazobactam and ceftazidime-avibactam against multidrug-resistant isolates of Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosaAdnan Alatoom, Hashim Elsayed, Karen Lawlor, et al.
Hemodialysis International. International Symposium on Home Hemodialysis|May 5, 2023
Microbiologic outcomes of ceftazidime-avibactam dosing in patients with sepsis utilizing renal replacement therapiesWasim S El Nekidy, Mooza Al Ali, Emna Abidi, et al.
The International Journal of Artificial Organs|July 30, 2024
Efficacy and safety of ertapenem dosing in patients with ESBL producing <i>Enterobacterales</i> infections utilizing renal replacement therapiesWasim S El Nekidy, Iyad Ghazal, Emna Abidi, et al.
Hospital Pharmacy|July 28, 2022
Is Cefoxitin a Carbapenem Sparing Agent in the Management of Urinary Tract Infections Caused by ESBL Producing <i>Enterobacterales</i>?Wasim S El Nekidy, Manal M Abdelsalam, Ahmad R Nusair, et al.
Antibiotics (Basel, Switzerland)|August 29, 2024
Clinical Outcomes of Ceftazidime-Avibactam versus Ceftolozane-Tazobactam in Managing Pseudomonal Infections in Patients Undergoing Renal Replacement TherapyWasim S El Nekidy, Mooza Al Ali, Emna Abidi, et al.
Antibiotics (Basel, Switzerland)|October 25, 2024
The Impact of Clinical Pharmacist-Driven Weekend Antimicrobial Stewardship Coverage at a Quaternary HospitalHazem Elrefaei, Wasim S El Nekidy, Rama Nasef, et al.
Pharmacotherapy|February 6, 2016
Therapeutic Advances in HCV Genotype 1 Infection: Insights from the Society of Infectious Diseases PharmacistsPaulina Deming, Michelle T Martin, Juliana Chan, et al.
Pageof 3